In summary, our results indicate that MGB1 expression is increased in breast cancer cells that have gained resistance to trastuzumab, and suggest that MGB1 promotes aggressiveness through cyclin and NF‐κB regulation. The gene discussed is SCGB2A2; the disease is breast carcinoma.